News headlines about PAVmed (NASDAQ:PAVM) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PAVmed earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.4667784298686 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Separately, Dawson James reiterated a “buy” rating and issued a $10.10 target price on shares of PAVmed in a research report on Tuesday, September 5th.
PAVmed (PAVM) opened at $2.22 on Friday. PAVmed has a 12-month low of $1.90 and a 12-month high of $9.31. The company has a current ratio of 0.42, a quick ratio of 0.42 and a debt-to-equity ratio of -0.26.
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.